Servais, L.
Boschetti, G.
Meunier, C.
Gay, C.
Cotte, E.
François, Y.
Rozieres, A.
Fontaine, J.
Cuminal, L.
Chauvenet, M.
Charlois, A. L.
Isaac, S.
Traverse-Glehen, A.
Roblin, X.
Flourié, B.
Valette, P. J.
Nancey, S.
Article History
Received: 15 May 2020
Accepted: 24 May 2021
First Online: 30 May 2021
Declarations
:
: Laure Servais: None. Gilles Boschetti: consulting fees from Merck, Abbvie, Takeda, Janssen Cilag, Hospira, Takeda. Camille Meunier: None. Claire Gay: None. Eddy Cotte: consulting fees from Takeda, Abbvie. Yves François: None. Aurore Rozieres: None; Juliette Fontaine: None. Lydie Cuminal: None. Marion Chauvenet: None. Anne-Laure Charlois: None. Sylvie Isaac: None. Alexandra Traverse-Glehen: None. Xavier Roblin served as a speaker, a consultant and/or an advisory board member for MSD, Pfizer, Janssen, Takeda, Abbvie, Amgen, Biogen, Gilead, Roche, Gilead, Theradiag. Bernard Flourié served as a speaker, a consultant and/or an advisory board member for MSD, Abbvie, Ferring, Norgine, Biocodex. Pierre-Jean Valette: None. Stéphane Nancey served as a speaker, a consultant and/or an advisory board member for Merck, Abbvie, Takeda, Ferring, Norgine, Vifor Pharma, Novartis, Janssen Cilag, Hospira, Takeda and HAC-Pharma.